{"id":59348,"date":"2024-05-10T13:04:27","date_gmt":"2024-05-10T11:04:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/"},"modified":"2024-05-10T13:04:27","modified_gmt":"2024-05-10T11:04:27","slug":"castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/","title":{"rendered":"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d"},"content":{"rendered":"
\n

\nThis marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions<\/i><\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CastleBiosciences<\/a>–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the \u201cBest Overall Mental Health Solution\u201d award in the eighth annual MedTech Breakthrough Awards program for its IDgenetix\u00ae pharmacogenomic (PGx) test. The MedTech Breakthrough Awards honor excellence and recognize innovation, hard work and success in a range of health and medical technology categories, attracting thousands of nominations from over 18 countries across the world.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cNearly half of all Americans will meet the criteria to be diagnosed with a mental health condition at some point during their life,\u201d1<\/sup> said Derek Maetzold, president and chief executive officer of Castle Biosciences. \u201cThis stark reality underscores the critical need for advanced tests like IDgenetix that can improve medication management for those struggling with neuropsychiatric conditions.\u201d<\/p>\n

\n\u201cBy taking into account lifestyle factors and drug-drug interactions in addition to drug-gene interactions, IDgenetix provides invaluable information that may impact a patient\u2019s response to medications,\u201d said Steve Johansson, managing director, MedTech Breakthrough. \u201cSo many patients with major depressive disorder don\u2019t achieve remission even after trying multiple medications. Others don’t achieve remission until trying four or more medications, delaying critical relief for those struggling with the daily challenges of their conditions. IDgenetix is designed to arm clinicians with personalized health information to help guide medication selection and management decisions, so patients can potentially achieve remission from their neuropsychiatric condition faster.\u201d<\/p>\n

\n\u201cMay is Mental Health Month, and receiving this recognition now makes it even more meaningful, as we strive to improve mental health care through personalized PGx testing,” continued Maetzold. \u201cWe are incredibly honored to have earned a fourth MedTech Breakthrough Award for our innovative tests designed to improve patient care.\u201d<\/p>\n

\nObserved each May, Mental Health Month was founded by Mental Health America (MHA) to promote awareness, provide vital resources and education, and advocate for the mental health and well-being of all people living in the United States. Castle is proud to be a platinum sponsor of MHA in 2024, which marks the 75th year since the organization launched Mental Health Week, which later evolved into Mental Health Month.<\/p>\n

\nIDgenetix is Castle Biosciences’ advanced precision medicine test that offers clinicians an objective way to choose or modify neuropsychiatric medication for their patients with mental health conditions. By combining pharmacogenomics (PGx) \u2014 the practice of analyzing a patient\u2019s DNA for pharmacogenetic biomarkers that may influence response to medication \u2014 with drug-drug interactions and lifestyle factor data, IDgenetix can help facilitate a more informed approach to mental health care in patients suffering from 10 neuropsychiatric conditions. While currently available PGx tests include information on genetic variants that may affect the efficacy or side-effect profile of a prescribed medication, Castle believes IDgenetix offers more by also considering lifestyle factors and drug-drug interactions. Randomized controlled study data presented at Psych Congress 2023 showed that integrating drug-gene, drug-drug and lifestyle factors provides 75% more guided information compared to traditional drug-gene interactions alone.2<\/sup><\/p>\n

\nCastle has previously won three consecutive MedTech Breakthrough Awards: \u201cBest Use of Artificial Intelligence in Healthcare\u201d in 2023 for its TissueCypher\u00ae Barrett’s Esophagus test, \u201cBest New Technology Solution \u2014 Dermatology\u201d in 2022 for its DecisionDx\u00ae-Melanoma gene expression profile (GEP) test, and \u201cBest New Technology Solution \u2014 Oncology\u201d in 2021 for its DecisionDx\u00ae-SCC and DiffDx\u00ae-Melanoma GEP tests.<\/p>\n

\nAbout MedTech Breakthrough<\/b><\/p>\n

\nPart of Tech Breakthrough<\/a>, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information, visit MedTechBreakthrough.com<\/a>.<\/p>\n

\nAbout Mental Health America<\/b><\/p>\n

\nMental Health America (MHA) is the nation’s leading national nonprofit dedicated to the promotion of mental health, well-being and illness prevention. MHA\u2019s work is informed, designed, and led by the lived experience of those most affected. Operating nationally and in communities across the country, MHA advocates for closing the mental health equity gap while increasing nationwide awareness and understanding through public education, direct services, tools and research. MHA\u2019s annual State of Mental Health in America report is among the most widely respected health reports in the nation. Visit MHANational.org<\/a> for more information.<\/p>\n

\nAbout IDgenetix<\/b><\/p>\n

\nIDgenetix is a pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient\u2019s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. IDgenetix is designed to provide important genetic information to clinicians to help guide personalized treatment plans for their patients, with the potential to help patients achieve a faster therapeutic response and improve their chances of remission by identifying appropriate medications more efficiently than the standard of care trial-and-error approach. IDgenetix provides drug-drug and drug-gene interactions and is supported by a published, peer-reviewed randomized controlled trial that observed clinical utility over the standard of care when physicians used IDgenetix prior to prescribing a medication. IDgenetix is currently reimbursed by Medicare for the following eight mental health conditions: major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, panic disorder, obsessive-compulsive personality disorder, post-traumatic stress disorder and attention deficit hyperactivity disorder.<\/p>\n

\nAbout Castle Biosciences<\/b><\/p>\n

\nCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.<\/p>\n

\nCastle\u2019s current portfolio consists of tests for skin cancers, Barrett\u2019s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com<\/a> and connect with us on LinkedIn<\/a>, Facebook<\/a>, X<\/a> and Instagram<\/a>.<\/p>\n

\nDecisionDx-Melanoma, DecisionDx-CMSeq<\/i>, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq<\/i> are trademarks of Castle Biosciences, Inc.<\/p>\n

    \n
  1. \nMental Health America; https:\/\/mhanational.org\/mentalhealthfacts<\/a>; accessed 4\/23\/24<\/li>\n
  2. \nThe Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial; https:\/\/castlebiosciences.com\/Scientific%20Evidence\/Files\/MH_01_002%20Psych%20Congress%20Final%20Upload.pdf<\/a><\/li>\n<\/ol>\n

    \nForward-Looking Statements<\/b><\/p>\n

    \nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the \u201csafe harbor\u201d created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of IDgenetix to (i) improve medication management for those struggling with neuropsychiatric conditions; (ii) provide invaluable information that may impact a patient\u2019s response to medications; (iii) arm clinicians with personalized health information to help guide medication selection and management decisions to help patients potentially achieve remission from their neuropsychiatric condition faster; and (iv) help facilitate a more informed approach to mental health care in patients suffering from 10 neuropsychiatric conditions. The words \u201ccan,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results shown in this study, including with respect to the discussion of IDgenetix in this press release; actual application of our IDgenetix test may not provide the aforementioned benefits to patients; and the risks set forth under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.<\/i><\/p>\n

    Contacts<\/b> <\/p>\n

    \nInvestor Contact:
    \n
    <\/b>Camilla Zuckero
    \n
    czuckero@castlebiosciences.com<\/a><\/p>\n

    \nMedia Contact:<\/b>
    Allison Marshall
    \n
    amarshall@castlebiosciences.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the \u201cBest Overall Mental Health Solution\u201d … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59348","6":"format-standard","7":"category-industry"},"yoast_head":"\nCastle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the \u201cBest Overall Mental Health Solution\u201d ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-10T11:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240510837170\/en\/2126533\/22\/CastleLogo2Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d\",\"datePublished\":\"2024-05-10T11:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/\"},\"wordCount\":1468,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240510837170\\\/en\\\/2126533\\\/22\\\/CastleLogo2Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/\",\"name\":\"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240510837170\\\/en\\\/2126533\\\/22\\\/CastleLogo2Color.jpg\",\"datePublished\":\"2024-05-10T11:04:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240510837170\\\/en\\\/2126533\\\/22\\\/CastleLogo2Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240510837170\\\/en\\\/2126533\\\/22\\\/CastleLogo2Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/","og_locale":"en_US","og_type":"article","og_title":"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d - Pharma Trend","og_description":"This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CastleBiosciences–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the \u201cBest Overall Mental Health Solution\u201d ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/","og_site_name":"Pharma Trend","article_published_time":"2024-05-10T11:04:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240510837170\/en\/2126533\/22\/CastleLogo2Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d","datePublished":"2024-05-10T11:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/"},"wordCount":1468,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240510837170\/en\/2126533\/22\/CastleLogo2Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/","url":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/","name":"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240510837170\/en\/2126533\/22\/CastleLogo2Color.jpg","datePublished":"2024-05-10T11:04:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240510837170\/en\/2126533\/22\/CastleLogo2Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240510837170\/en\/2126533\/22\/CastleLogo2Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/castle-biosciences-idgenetix-test-receives-2024-medtech-breakthrough-award-for-best-overall-mental-health-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Castle Biosciences\u2019 IDgenetix\u00ae Test Receives 2024 MedTech Breakthrough Award for \u201cBest Overall Mental Health Solution\u201d"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59348"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59348\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}